期刊文献+

慢性肾功能不全对药动学影响研究进展 被引量:12

Advances of the influence of chronic renal failure on the pharmacokinetics
暂未订购
导出
摘要 慢性肾功能不全是临床常见疾病之一,主要经肾消除及主要经非肾途径消除的药物,药代动力学及药效学均受慢性肾功能不全疾病的影响。肾功能不全尤其是终末期肾病不仅直接减少药物的排泄,还能影响药物吸收、药物转运及药物代谢,从而影响药物的非肾消除。肾功能不全可直接抑制药物代谢酶及转运体的活性并减少酶及转运体在胃肠道、肝脏等多个器官的mRNA及蛋白的表达。引起这种抑制作用的原因尚不明确,血液透析可以部分抵消或逆转这种抑制作用并存在透析消除。 The chronic renal failure(CRF) is one of the common diseases in clinic. CRF affects the pharmacokinetics and pharmacodynamics of drug which either eliminate by renal or by nonrenal routes. The tests in vivo and in vitro demonstrated that renal impairment especially end-stage renal disease (ESRD) not only decreased the excretion by kidney, but also the alterations in the activities of and interplay between uptake and efflux transporters and metabolic enzymes significantly affected the PK disposition and resulting exposure of drugs cleared through nonrenal. CRF can directly inhibit the activity of various metabolic enzymes and transporters and in the other sides the CRF can downregulate the mRNA and protein expression of metabolic enzymes and multiple intestinal and hepatic drug transporters. The reasons of those inhibition effects need more researches. The hemodialysis can partially offset or reverse this kinds of inhibition and dialysis clearance exist in the patient with ESRD.
出处 《中国临床药理学与治疗学》 CAS CSCD 2012年第6期715-720,共6页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 肾功能不全 药动学 研究进展 Chronic renal failure Pharmaco- kinetics Advances
  • 相关文献

参考文献30

  • 1Coresh J, Selvin E, Stevens LA,et al. Prevalence of chronic kidney disease in the United States[J]. JAMA, 2007,298(17) :2038-2047.
  • 2Zhang L, Zhang P, Wang F, et al. Prevalence and factors associated with CKD: a population study from Beijing[J]. Am J Kidney Dis,2008, 51(3) : 373-384.
  • 3Evans RS, Lloyd JF, Stoddard GJ, et al. Risk factors for adverse drug events: a 10-year anaIysis[J]. Ann Pharmacother, 2005, 89(7/8) : 1161- 1168.
  • 4Manley H J, Cannella CA, Bailie GR,et al. Medication-related problems in ambulatory hemodialysis patients, a pooled analysis[J]. Am J Kidney Dis, 2005,46(4) :669-680.
  • 5AW Dreisbach. The influence of Chronic Renal Failure on drug metabolism and transport[J]. Clin Pharmacol Ther, 2009,86(5) :553-556.
  • 6Leblond FA, Giroux L, Villeneuve JP, et al. Decreased in vivo metabolism of drugs in chronic renal failure[J]. Drug Metab Dispos, 2000 , 28 (11): 1317-1320.
  • 7Leblond FA, Petrueci M, Dube P, et al. Downregulation of intestinal cytoehrome P450 in chronic renal failure[J]. J Am Soc Nephrol, 2002,13 (6) 1579-1585.
  • 8Dani M, Boisvert C, Michaud J, et al . Downregulation of liver drug metabolizing enzymes in a murine model of chronic renal failure[J]. J Am J Physiol Renal Physiol, 2010,38(3) :357-360.
  • 9李晓宇,刘皋林.CYP450酶特性及其应用研究进展[J].中国临床药理学与治疗学,2008,13(8):942-946. 被引量:55
  • 10Karara AH, Frye RF, Hayes PE, et al. Pharmacokinetics of abecarnil in patients with renal insuffieieney[J]. Clin Pharmaeol Ther, 1996,59 (5): 520 -528.

二级参考文献47

共引文献57

同被引文献173

引证文献12

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部